Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03169101 · ClinicalTrials.gov registry record

Cognition and Smoking Relapse (HCS)

A clinical trial of Smoking Cessation, sponsored by University of Pennsylvania.

Completed
Registry status
274
Enrollment target
1
Study location

NCT03169101 is a study of Smoking Cessation that has completed, run by University of Pennsylvania. The registered enrollment target is 274 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03169101, a study of Smoking Cessation, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
274 participants
Enrollment target
1
Study location

Study Summary

This study tests whether withdrawal-related cognitive deficits increase smoking relapse among HIV-infected (HIV+) vs. HIV-uninfected smokers (HIV-). Adult smokers (N=300; 150 HIV+, 150 HIV-) will complete 2 sessions to assess cognition (24h abstinence vs. smoking-as-usual; order counterbalanced; weeks 0-2). Subjects will then receive smoking cessation counseling and open label transdermal nicotine (weeks 3-12). Outcomes are: 1) cognition; and 2) abstinence rates at the end-of-treatment.

Conditions Studied

Interventions

  • BEHAVIORAL Behavioral counseling
  • DRUG Nicotine patch

Study Locations (1)

Pennsylvania

  • Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2016-07-01
Est. Completion 2022-04-25

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT03169101

The ClinicalTrials.gov registry entry for NCT03169101 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (42% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Behavioral counseling is the first listed.

NCT03169101 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03169101 about?

NCT03169101 is a clinical study titled "Cognition and Smoking Relapse (HCS)". This study tests whether withdrawal-related cognitive deficits increase smoking relapse among HIV-infected (HIV+) vs. HIV-uninfected smokers (HIV-). Adult smokers (N=300; 150 HIV+, 150 HIV-) will complete 2 sessions to assess cognition (24h abstinence vs. smoking-as-usual; order counterbalanced; wee...

What is the current status of trial NCT03169101?

This trial is currently completed. The enrollment target is 274 participants. The study started on 2016-07-01. Estimated completion is 2022-04-25.

What conditions does trial NCT03169101 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT03169101?

The interventions under investigation include: Behavioral counseling (BEHAVIORAL), Nicotine patch (DRUG).

Who is sponsoring clinical trial NCT03169101?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03169101 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.